Original articles

Is the use of a GnRH antagonist effective in patients with polycystic ovarian syndrome? A South African perspective

T I Siebert, T F Kruger, C L Grieve, D W Steyn

Abstract


Introduction. Polycystic ovarian disease (PCOS) can account for up to 35 - 40% of the female factor causes of infertility. These patients present as medically complex cases and are challenging to manage and treat successfully. They are resistant to treatment and are often offered controlled ovarian stimulation (COS) and in vitro fertilisation (IVF) technology.
Aim. The aim of this study was to assess whether there was a difference in the pregnancy outcomes of women with PCOS when a standard gonadotrophin-releasing hormone (GnRH) antagonist (cetrorelix) protocol was used for ovarian stimulation, compared with non-PCOS patients undergoing IVF.
Methods. A retrospective patient record audit was performed on 142 patients with PCOS and 501 non-PCOS patients undergoing a similar cetrorelix-based COS treatment protocol during a specified time period.
Results. The main primary outcome was an ongoing pregnancy at 12 weeks, achieved in 34% of patients in the PCOS group and 27% in the non-PCOS group. This was not significantly different (p=0.07). No patient in the PCOS group experienced severe hyperstimulation syndrome.
Conclusion. There was no significant difference in pregnancy rates in patients with PCOS undergoing GnRH-antagonist ovarian stimulation compared with non-PCOS patients. The fact that no hyperstimulation syndrome occurred makes this an attractive option for women with PCOS.

Authors' affiliations

T I Siebert, Stellenbosch University

T F Kruger, Stellenbosch University

C L Grieve,

D W Steyn, Stellenbosch University

Full Text

PDF (130KB) HTML

Keywords

PCOS; GnRh antagonists; Pregnancy rates

Cite this article

South African Journal of Obstetrics and Gynaecology 2012;18(1):11-14.

Article History

Date submitted: 2011-06-30
Date published: 2012-01-19

Article Views

Abstract views: 2099
Full text views: 4908

Comments on this article

*Read our policy for posting comments here